Detection of promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients
- PMID: 15251937
- DOI: 10.1196/annals.1318.007
Detection of promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients
Erratum in
- Ann N Y Acad Sci. 2012 Apr;1254. doi:10.1111/j.1749-6632.2011.06583.x
-
Corrigendum for Ann. N.Y. Acad. Sci. 1022: 40-43.Ann N Y Acad Sci. 2012 Apr;1254(1):175. doi: 10.1111/j.1749-6632.2011.06583.x. Ann N Y Acad Sci. 2012. PMID: 36076728 No abstract available.
Abstract
Kidney cancer is curable by surgical resection and therapy, if detected at an early stage. Using sensitive methylation-specific polymerase chain reaction, we screened matched tumor DNA and preoperative urine DNA from 50 kidney cancer patients, for hypermethylation of a panel of six normally unmethylated tumor suppressor genes: VHL, p16/CDKN2a, p14ARF, APC, RASSF1A, and Timp-3. When compared to the tumor DNA, an identical pattern of gene hypermethylation was found in the matched urine DNA from 44 of 50 patients (88% sensitivity) including 27 of 30 cases of stage I disease. By contrast, hypermethylation was not observed in normal and benign disease controls (100% specificity). We conclude that promoter hypermethylation is a common and early event in kidney tumorigenesis and can be detected in the urine DNA from patients with organ-confined renal cancer of all histologic types.
Similar articles
-
Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients.Cancer Res. 2003 Dec 15;63(24):8695-9. Cancer Res. 2003. PMID: 14695183
-
Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel.Clin Cancer Res. 2004 Mar 15;10(6):1887-93. doi: 10.1158/1078-0432.ccr-03-0127. Clin Cancer Res. 2004. PMID: 15041703
-
Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer.Cancer Res. 2004 Aug 1;64(15):5511-7. doi: 10.1158/0008-5472.CAN-04-0799. Cancer Res. 2004. PMID: 15289362
-
Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients.Cancer Res. 2004 Sep 15;64(18):6476-81. doi: 10.1158/0008-5472.CAN-04-1529. Cancer Res. 2004. PMID: 15374957
-
Promoter methylation status of tumor suppressor and tumor-related genes in neoplastic and non-neoplastic gastric epithelia.Histol Histopathol. 2004 Jan;19(1):221-8. doi: 10.14670/HH-19.221. Histol Histopathol. 2004. PMID: 14702190 Review.
Cited by
-
The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients.Int J Mol Sci. 2013 Sep 13;14(9):18925-58. doi: 10.3390/ijms140918925. Int J Mol Sci. 2013. PMID: 24065096 Free PMC article. Review.
-
Therapeutic targets in the ARF tumor suppressor pathway.Curr Med Chem. 2007;14(17):1815-27. doi: 10.2174/092986707781058869. Curr Med Chem. 2007. PMID: 17627519 Free PMC article. Review.
-
Implications of storing urinary DNA from different populations for molecular analyses.PLoS One. 2009 Sep 10;4(9):e6985. doi: 10.1371/journal.pone.0006985. PLoS One. 2009. PMID: 19746164 Free PMC article.
-
Molecular characterization of head and neck cancer: how close to personalized targeted therapy?Mol Diagn Ther. 2012 Aug 1;16(4):209-22. doi: 10.2165/11635330-000000000-00000. Mol Diagn Ther. 2012. PMID: 22873739 Free PMC article.
-
The promise of methylation on beads for cancer detection and treatment.Expert Rev Mol Diagn. 2014 Sep;14(7):845-52. doi: 10.1586/14737159.2014.943665. Expert Rev Mol Diagn. 2014. PMID: 25136840 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous